The creation of the Canadian company Lemer Pax America will be officially announced at the 35th edition of the SNMMI (Society of Nuclear Medicine & Molecular Imaging) in Chicago on June 24-27 by Pierre-Marie Lemer, President of Lemer Pax, and Stéphane Leduc, General Manager of CCNuclear.
Aim: To establish operations in the North American nuclear medicine market (Canada, United States and Mexico)
The US market alone represents 50% of the global nuclear medicine market and is experiencing strong growth in its radiopharmaceutical and theranostic components – areas where Lemer Pax cemented an early foothold.
Lemer Pax America has been created to roll out the Lemer Pax range, tailored to the specific regulations of the North-American markets in the field of nuclear medicine, and to ultimately become an established brand on the North-American continent. Over USD 2 million worth of business has already been secured in North America, the aim being to increase that figure to USD 50 million within 5 years and to develop a fully-fledged center of excellence devoted to nuclear medicine in the Greater Montreal.
Stéphane Le Duc, CCN General Director
The first equipment to cross the Atlantic will be the shielded hot cells for the preparation of radiotracers dedicated to nuclear medicine, of the Easypharma Compact® type, syringe shields and other storage solutions as well as the shielded injection system for theranostic products, Theranojet®RIO.
There are strong growth prospects in nuclear medicine at the moment, with the opening of markets to therapy and the convergence of North American standards closer in line with European standards. Lemer Pax’s management team therefore considers this a good time to target the North-American market.
This is the right time for us to offer our solutions complying with the new requirements of the North American authorities in terms of health. Our radiation protection solutions are in advance as regards to standards, something which professionals readily acknowledge. The hallmarks of our nuclear medicine range – ergonomics, quality and technology – are widely respected
Pierre-Marie Lemer, Lemer Pax President
Initially, the radiation protection solutions will be produced and assembled in France, while Lemer Pax America’s local teams will install them on-site. The first step is to promote the Lemer Pax America brand across the North American continent, by building sales, and, in the medium term, developing radiation protection solutions across the Atlantic.
The North American market therefore harbors tremendous growth potential, but it is also very demanding. That’s why benefiting from an experienced partner over there who is familiar with the market strikes me as the right solution, for a win-win agreement for the benefit of users
From left to right, Valérie Chevreul, Lemer Pax Chief Executive Officer, Stéphane Leduc, CCNuclear General Manager and Pierre-Marie Lemer, Lemer Pax President
On the Board of Directors of Lemer Pax America, whose registered office is based in Montreal, Lemer Pax will be represented by Pierre-Marie Lemer, President, and Valérie Chevreul, General Director, and CCN by Stéphane Leduc, its General Manager, and Philippe Lacoste, Chief Operating Officer.
For Frank Hebert, Sales Director at Lemer Pax America, who has more than 25 years of expertise in the nuclear medicine field in North America, the timing of this move is to be applauded.
The strong growth of radiotheranostics is bringing new therapeutic solutions for many cancer patients. The very best technology is needed to support the swift development of this emerging sector. Lemer Pax America’s innovative and highly ergonomic range in this field will meet this need perfectly.
Frank Hebert, Lemer Pax America Sales Director
